Wuhan HUST Life Science & Technology Co., Ltd., jointly invested by Wuhan HUST High-Tech Group Ltd., Wuhan Huagong Venture Capital Co., Ltd. and Wuhan HUST Nano Medicine Co., Ltd., was established as an API enterprise in June 2005, specializing in manufacturing and distributing active pharmaceutical ingredient, preparation, pharmaceutical intermediate, and chemical products, researching and developing chemical pharmaceutical products and support technology service. Seated in HUST Sci-tech, based on technology development of HUST (Huazhong University of Science & Technology), Hust-Life is devoted itself to be the top-notch pharmaceutical manufacturer with technology advantage in the filed of amylose. The newly-built Hust-Life API Base, with a 10000 M2 area, has a 3000 M2 chemical API workshop conforming to GMP standard, equipped with facilities for high temperature, high-atmospheric pressure, cryogenic and other chemosynthesis processing, it has the ability of production on a large scale. Hust-Life adopts advanced chemosynthesis technology, and its API industrialization fills up the gap in the domestic filed. The first industrialized API item — medium Molecular Weight (MW) Hydroxyethyl Starch (HES) 200/0.5 is a popular plasma substitute in Europe, and the preferred remedy in curing and de ng deficient blood volume and shock. It takes the lead in technology and will form a series of high & medium MW plasma substitute gradually. Hust –Life, like a seed, demonstrates its vigor during growth. With the enterprise culture “high efficiency, preciseness, conciseness & cooperation”, depending on highly professional technology & management personnel, excellent manufacture technology and superior quality, it bases itself on domestic market, faces international market, enhances the development, and is trying its best to contribute to the society.